Skip to content

Dyspnea in Patients With Pulmonary Fibrosis

Dyspnea in Patients With Pulmonary Fibrosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00611182
Enrollment
60
Registered
2008-02-08
Start date
2008-01-31
Completion date
2010-03-31
Last updated
2013-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Fibrosis

Keywords

dyspnea, pulmonary fibrosis, interstitial lung disease, shortness of breath

Brief summary

This study has two aims: 1. To determine the relationship of shortness of breath (dyspnea) to other conditions present in patients with pulmonary fibrosis. 2. To define the relationship between shortness of breath and rate of functional decline in patients with pulmonary fibrosis.

Detailed description

Idiopathic Pulmonary Fibrosis is the most common form of chronic fibrosing lung disease seen by pulmonologists, with an estimated 128,000 cases in the United States alone. It is almost surely a disorder related to aging, with a median age at the time of diagnosis of approximately 65 years; IPF is almost unheard of under the age of 50. Dyspnea is common in patients with IPF, and is often the primary symptom of the disease. It is tightly linked to quality of life in IPF, suggesting that the experience of dyspnea has wide-ranging and clinically-significant consequences. Despite its importance, surprisingly little is known about the etiology or functional impact of dyspnea in this disease. This research proposal focuses on defining the relationship of dyspnea to comorbidity and the rate of functional decline in patients with IPF Aim 1: To determine the relationship of dyspnea to other conditions present in patients with IPF. Dyspnea is a complex symptom, related to both mechanical and cognitive factors. The mechanisms of dyspnea in IPF remain unknown, but there are several likely contributors that are both IPF and non-IPF related. Although IPF is a chronic disease of the elderly, no one has investigated the relationship between common geriatric conditions and dyspnea. It is well established that the perception of dyspnea depends equally on factors that influence the intensity of the experience of breathlessness (such as thoracic restriction and weakness) and the distress which that intensity produces. Gender, ethnicity, anxiety, pain, and depression all may contribute to the distress caused by dyspnea (and therefore its intensity) in IPF. Aim 2: To define the relationship between dyspnea and rate of functional decline in IPF. Numerous studies have looked at predictors of survival in patients with IPF, and both baseline and change in dyspnea over time have been shown to be significantly associated. The prediction of future morbidity, however, is largely unstudied. Established markers of functional decline in geriatric patients include weight loss, decline in walking speed over 4 meters, and the onset of disability as defined by the ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs). Dyspnea likely impacts patients' activity levels and/or motivation to stay active, and may contribute to worsening functional decline.

Interventions

None listed

Sponsors

University of Chicago
CollaboratorOTHER
American College of Chest Physicians
CollaboratorOTHER
The John A. Hartford Foundation
CollaboratorOTHER
Association of Specialty Physicians, Inc.
CollaboratorINDUSTRY
University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age and older with pulmonary fibrosis, and able to travel to University of California San Francisco for study visits

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Dyspnea6 months

Secondary

MeasureTime frame
Functional status6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026